IBIO
Price
$0.85Alerts
Change
+$0.10 (+13.33%)
Updated
Nov 18 closing price
Capitalization
47.5M
90 days until earnings call
Intraday BUY SELL Signals
KYMR
Price
$121.13Alerts
Change
-$0.39 (-0.32%)
Updated
Nov 18 closing price
Capitalization
10.95B
99 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IBIO vs KYMR

IBIO vs KYMR Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
IBIO vs. KYMR commentary
Nov 19, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IBIO is a Buy and KYMR is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for IBIO with price predictions
Nov 18, 2026

IBIO sees its Stochastic Oscillator ascends from oversold territory

On November 18, 2026, the Stochastic Oscillator for IBIO moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 61 instances where the indicator left the oversold zone. In 56 of the 61 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IBIO's RSI Oscillator exited the oversold zone, 34 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.

The Momentum Indicator moved above the 0 level on November 18, 2026. You may want to consider a long position or call options on IBIO as a result. In 68 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.

The Moving Average Convergence Divergence (MACD) for IBIO just turned positive on October 27, 2026. Looking at past instances where IBIO's MACD turned positive, the stock continued to rise in 32 of 39 cases over the following month. The odds of a continued upward trend are 82%.

Following a +20.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBIO advanced for three days, in 186 of 223 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

The Aroon Indicator for IBIO entered a downward trend on November 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.554) is normal, around the industry mean (3.592). P/E Ratio (-2.308) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (1250.000) is also within normal values, averaging (442.120).

The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. IBIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for KYMR with price predictions
Nov 18, 2026

KYMR in +8.38% Uptrend, growing for three consecutive days on November 09, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where KYMR advanced for three days, in 239 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

KYMR moved above its 50-day moving average on October 27, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for KYMR crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.

The Aroon Indicator entered an Uptrend today. In 144 of 183 cases where KYMR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.

Bearish Trend Analysis

The 10-day RSI Indicator for KYMR moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In 37 of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.

The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KYMR as a result. In 69 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for KYMR turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 39 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KYMR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

KYMR broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.258) is normal, around the industry mean (3.592). P/E Ratio (-40.532) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (103.093) is also within normal values, averaging (442.120).

The Tickeron Profit vs. Risk Rating rating for this company is 35 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. KYMR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
IBIO vs KYMR: Fundamental Ratings
IBIO
KYMR
OUTLOOK RATING
1..100
3175
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
5
Undervalued
PROFIT vs RISK RATING
1..100
10035
SMR RATING
1..100
9895
PRICE GROWTH RATING
1..100
8036
P/E GROWTH RATING
1..100
1171
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KYMR's Valuation (5) in the null industry is somewhat better than the same rating for IBIO (69) in the Biotechnology industry. This means that KYMR’s stock grew somewhat faster than IBIO’s over the last 12 months.

KYMR's Profit vs Risk Rating (35) in the null industry is somewhat better than the same rating for IBIO (100) in the Biotechnology industry. This means that KYMR’s stock grew somewhat faster than IBIO’s over the last 12 months.

KYMR's SMR Rating (95) in the null industry is in the same range as IBIO (98) in the Biotechnology industry. This means that KYMR’s stock grew similarly to IBIO’s over the last 12 months.

KYMR's Price Growth Rating (36) in the null industry is somewhat better than the same rating for IBIO (80) in the Biotechnology industry. This means that KYMR’s stock grew somewhat faster than IBIO’s over the last 12 months.

IBIO's P/E Growth Rating (11) in the Biotechnology industry is somewhat better than the same rating for KYMR (71) in the null industry. This means that IBIO’s stock grew somewhat faster than KYMR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IBIOKYMR
RSI
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 1 day ago
86%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
81%
Momentum
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
87%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
78%
Advances
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 10 days ago
82%
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 1 day ago
86%
BollingerBands
ODDS (%)
N/A
Bearish Trend 1 day ago
78%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
79%
COMPARISON
Comparison
Nov 19, 2026
Stock price -- (IBIO: $0.75 vs. KYMR: $121.52)
Brand notoriety: IBIO and KYMR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IBIO: 57% vs. KYMR: 87%
Market capitalization -- IBIO: $47.5M vs. KYMR: $10.95B
IBIO [@Biotechnology] is valued at $47.5M. KYMR’s [@Biotechnology] market capitalization is $10.95B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IBIO’s FA Score shows that 1 FA rating(s) are green while KYMR’s FA Score has 2 green FA rating(s).

  • IBIO’s FA Score: 1 green, 4 red.
  • KYMR’s FA Score: 2 green, 3 red.
According to our system of comparison, KYMR is a better buy in the long-term than IBIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IBIO’s TA Score shows that 5 TA indicator(s) are bullish while KYMR’s TA Score has 5 bullish TA indicator(s).

  • IBIO’s TA Score: 5 bullish, 3 bearish.
  • KYMR’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, IBIO is a better buy in the short-term than KYMR.

Price Growth

IBIO (@Biotechnology) experienced а -4.09% price change this week, while KYMR (@Biotechnology) price change was -11.07% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -11.10%. For the same industry, the average monthly price growth was -10.38%, and the average quarterly price growth was -24.10%.

Reported Earning Dates

IBIO is expected to report earnings on Feb 16, 2027.

KYMR is expected to report earnings on Feb 25, 2027.

Industries' Descriptions

@Biotechnology (-11.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

IBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, IBIO has been loosely correlated with WVE. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if IBIO jumps, then WVE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IBIO
1D Price
Change %
IBIO100%
+13.37%
WVE - IBIO
47%
Loosely correlated
-2.46%
GPCR - IBIO
39%
Loosely correlated
-4.46%
REPL - IBIO
38%
Loosely correlated
+0.61%
KYMR - IBIO
37%
Loosely correlated
-0.32%
AVTX - IBIO
36%
Loosely correlated
-6.03%
More

KYMR and

Correlation & Price change

A.I.dvisor indicates that over the last year, KYMR has been loosely correlated with GPCR. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if KYMR jumps, then GPCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KYMR
1D Price
Change %
KYMR100%
-0.32%
GPCR - KYMR
63%
Loosely correlated
-4.46%
WVE - KYMR
54%
Loosely correlated
-2.46%
DYN - KYMR
49%
Loosely correlated
-0.94%
STOK - KYMR
46%
Loosely correlated
+1.06%
OCUL - KYMR
44%
Loosely correlated
-1.33%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
KAUG27.870.08
+0.28%
Innovator US Small Cap Power Buffer ETF - August (KAUG)
JANW39.13N/A
+0.01%
AllianzIM U.S. Equity Buffer20 Jan ETF (JANW)
GJS23.49N/A
N/A
Synthetic Fixed-Income Securities STRATS 2006-2 Goldman Sachs Group
BKWO37.72N/A
N/A
BNY Mellon Womens's Opportunities ETF
PAUG45.71-0.05
-0.11%
Innovator U.S. Equity Power Buffer ETF - August (PAUG)